Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol
N/A
9 Years
46 Years
9 Years
46 Years
Not Enrolling
Both
Papillomavirus Infections
Both
Papillomavirus Infections
Trial Information
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol
Inclusion Criteria:
- Received GARDASIL™
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Cross-Sectional
Outcome Measure:
Number of participants with adverse events following any dose of vaccine
Outcome Time Frame:
At least 30 days following any vaccine dose
Safety Issue:
Yes
Authority:
Philippines: Bureau of Food and Drugs
Study ID:
V501-077
NCT ID:
NCT01355003
Start Date:
February 2008
Completion Date:
June 2010
Related Keywords:
- Papillomavirus Infections
- Papillomavirus Infections
Name | Location |
|---|
